vs
Side-by-side financial comparison of Hims & Hers Health, Inc. (HIMS) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $608.1M, roughly 1.2× Hims & Hers Health, Inc.). On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 3.8%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $53.0M). Over the past eight quarters, Hims & Hers Health, Inc.'s revenue compounded faster (38.8% CAGR vs 17.7%).
Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
HIMS vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $608.1M | $708.5M |
| Net Profit | — | $135.1M |
| Gross Margin | 65.2% | — |
| Operating Margin | 21.9% | 21.6% |
| Net Margin | — | 19.1% |
| Revenue YoY | 3.8% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $-0.40 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $608.1M | — | ||
| Q4 25 | $617.8M | $708.5M | ||
| Q3 25 | $599.0M | $659.9M | ||
| Q2 25 | $544.8M | $603.3M | ||
| Q1 25 | $586.0M | $558.6M | ||
| Q4 24 | $481.1M | $536.6M | ||
| Q3 24 | $401.6M | $533.3M | ||
| Q2 24 | $315.6M | $528.1M |
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $135.1M | ||
| Q3 25 | $15.8M | $111.1M | ||
| Q2 25 | $42.5M | $90.3M | ||
| Q1 25 | $49.5M | $114.6M | ||
| Q4 24 | $26.0M | $117.0M | ||
| Q3 24 | $75.6M | $96.4M | ||
| Q2 24 | $13.3M | $88.4M |
| Q1 26 | 65.2% | — | ||
| Q4 25 | 71.9% | — | ||
| Q3 25 | 73.8% | — | ||
| Q2 25 | 76.4% | — | ||
| Q1 25 | 73.5% | — | ||
| Q4 24 | 76.8% | — | ||
| Q3 24 | 79.2% | — | ||
| Q2 24 | 81.3% | — |
| Q1 26 | 21.9% | — | ||
| Q4 25 | 1.5% | 21.6% | ||
| Q3 25 | 2.0% | 21.5% | ||
| Q2 25 | 4.9% | 20.9% | ||
| Q1 25 | 9.9% | 20.3% | ||
| Q4 24 | 3.9% | 23.4% | ||
| Q3 24 | 5.6% | 21.1% | ||
| Q2 24 | 3.5% | 19.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 19.1% | ||
| Q3 25 | 2.6% | 16.8% | ||
| Q2 25 | 7.8% | 15.0% | ||
| Q1 25 | 8.4% | 20.5% | ||
| Q4 24 | 5.4% | 21.8% | ||
| Q3 24 | 18.8% | 18.1% | ||
| Q2 24 | 4.2% | 16.7% |
| Q1 26 | $-0.40 | — | ||
| Q4 25 | $0.08 | $4.65 | ||
| Q3 25 | $0.06 | $3.86 | ||
| Q2 25 | $0.17 | $3.10 | ||
| Q1 25 | $0.20 | $3.67 | ||
| Q4 24 | $0.10 | $3.67 | ||
| Q3 24 | $0.32 | $3.01 | ||
| Q2 24 | $0.06 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $222.3M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $446.2M | $459.1M |
| Total Assets | $2.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $222.3M | — | ||
| Q4 25 | $228.6M | $497.0M | ||
| Q3 25 | $345.8M | $285.4M | ||
| Q2 25 | $1.1B | $46.3M | ||
| Q1 25 | $273.7M | $441.4M | ||
| Q4 24 | $220.6M | $669.4M | ||
| Q3 24 | $165.5M | $656.9M | ||
| Q2 24 | $129.3M | $510.9M |
| Q1 26 | $446.2M | — | ||
| Q4 25 | $540.9M | $459.1M | ||
| Q3 25 | $581.0M | $293.6M | ||
| Q2 25 | $562.7M | $172.4M | ||
| Q1 25 | $549.3M | $593.6M | ||
| Q4 24 | $476.7M | $825.5M | ||
| Q3 24 | $440.1M | $881.4M | ||
| Q2 24 | $362.0M | $763.6M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.2B | $1.8B | ||
| Q2 25 | $1.9B | $1.6B | ||
| Q1 25 | $891.7M | $1.9B | ||
| Q4 24 | $707.5M | $2.1B | ||
| Q3 24 | $602.3M | $2.1B | ||
| Q2 24 | $480.5M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $89.4M | $192.7M |
| Free Cash FlowOCF − Capex | $53.0M | $188.1M |
| FCF MarginFCF / Revenue | 8.7% | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $60.3M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $89.4M | — | ||
| Q4 25 | $61.3M | $192.7M | ||
| Q3 25 | $148.7M | $246.2M | ||
| Q2 25 | $-19.1M | $148.5M | ||
| Q1 25 | $109.1M | $125.8M | ||
| Q4 24 | $86.4M | $190.7M | ||
| Q3 24 | $85.3M | $149.1M | ||
| Q2 24 | $53.6M | $116.4M |
| Q1 26 | $53.0M | — | ||
| Q4 25 | $-2.5M | $188.1M | ||
| Q3 25 | $79.3M | $235.5M | ||
| Q2 25 | $-69.5M | $142.4M | ||
| Q1 25 | $50.1M | $115.8M | ||
| Q4 24 | $59.5M | $183.0M | ||
| Q3 24 | $79.4M | $138.5M | ||
| Q2 24 | $47.6M | $103.5M |
| Q1 26 | 8.7% | — | ||
| Q4 25 | -0.4% | 26.6% | ||
| Q3 25 | 13.2% | 35.7% | ||
| Q2 25 | -12.8% | 23.6% | ||
| Q1 25 | 8.5% | 20.7% | ||
| Q4 24 | 12.4% | 34.1% | ||
| Q3 24 | 19.8% | 26.0% | ||
| Q2 24 | 15.1% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 10.3% | 0.6% | ||
| Q3 25 | 11.6% | 1.6% | ||
| Q2 25 | 9.3% | 1.0% | ||
| Q1 25 | 10.1% | 1.8% | ||
| Q4 24 | 5.6% | 1.4% | ||
| Q3 24 | 1.5% | 2.0% | ||
| Q2 24 | 1.9% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.98× | 1.43× | ||
| Q3 25 | 9.43× | 2.22× | ||
| Q2 25 | -0.45× | 1.65× | ||
| Q1 25 | 2.20× | 1.10× | ||
| Q4 24 | 3.32× | 1.63× | ||
| Q3 24 | 1.13× | 1.55× | ||
| Q2 24 | 4.03× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIMS
| United States Revenue | $529.9M | 87% |
| Rest of the World Revenue | $78.2M | 13% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
